GLP-1 Receptor Agonists or SGLT2 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy

This cohort study evaluates the 3-year risk of nonarteritic anterior ischemic optic neuropathy among veterans with type 2 diabetes who initiated glucagon-like peptide-1 receptor agonists (GLP-1RAs) or a sodium-glucose cotransporter-2 (SGLT2) inhibitor.

Corresponding Author: Yan Xie, PhD, VA St Louis Health Care System, 915 N Grand Blvd, 151-JC, St Louis, MO 63106 (yan.xie3@va.gov).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.